Emerging drugs for the treatment of tobacco dependence: 2014 update

Bibliography

• King B. Vital signs: current cigarette smoking among adults aged >/=18 years--United States, 2005-2010. MMWR Morb Mortal Wkly Rep 2011;60:1207-12
   PubMedGoogle Scholar
• World Health Organization. WHO report on the global tobacco epidemic, 2011. warning about the dangers of tobacco. World Health Organization; Geneva, Switzerland: 2011
   Google Scholar
• Giovino GA, Mirza SA, Samet JM, et al. Tobacco use in 3 billion individuals from 16 countries: an analysis of nationally representative cross-sectional household surveys. Lancet 2012;380:668-79
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. How tobacco smoke causes disease: the biology and behavioral basis for smoking-attributable disease: a report of the surgeon general. Department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health; Atlanta GA, USA; 2010
   Google Scholar
• U.S. Department of Health and Human Services. The health consequences of smoking-50 years of progress: a report of the surgeon general. Department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health; Atlanta GA, USA; 2014
   Google Scholar
• Jha P, Ramasundarahettige C, Landsman V, et al. 21st-Century hazards of smoking and benefits of cessation in the united states. N Engl J Med 2013;368:341-50
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses–United States, 2000-2004. MMWR Morb Mortal Wkly Rep 2008;57:1226-8
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. CDC fact sheet: smoking & tobacco use. 2012. Available from: http://www.cdc.gov/tobacco/data_statistics/fact_sheets/fast_facts/#cost [Last Accessed 30 January 2014]
   Google Scholar
• World Lung Foundation. New tobacco atlas estimates U.S. $35 billion tobacco industry profits and almost 6 million annual deaths. 2012. Available from: http://www.worldlungfoundation.org/ht/display/ReleaseDetails/i/20439/pid/6858 [Last Accessed 22 November 2013]
   Google Scholar
• Richard P, West K, Ku L. The return on investment of a Medicaid tobacco cessation program in Massachusetts. PLoS One 2012;7:e29665
   PubMed Web of Science ®Google Scholar
• Le Houezec J. Role of nicotine pharmacokinetics in nicotine addiction and nicotine replacement therapy: a review. Int J Tuberc Lung Dis 2003;7:811-19
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Nicotine addiction. N Engl J Med 2010;362:2295-303
   PubMed Web of Science ®Google Scholar
• Stolerman IP, Jarvis MJ. The scientific case that nicotine is addictive. Psychopharmacology (Berl) 1995;117:2-10; discussion 4-20
   PubMed Web of Science ®Google Scholar
• Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71
   PubMed Web of Science ®Google Scholar
• Brennan KA, Putt F, Truman P. Nicotine-, tobacco particulate matter- and methamphetamine-produced locomotor sensitisation in rats. Psychopharmacology (Berl) 2013;228:659-72
   PubMed Web of Science ®Google Scholar
• Laviolette SR, van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 2004;5:55-65
   PubMed Web of Science ®Google Scholar
• Leslie FM, Mojica CY, Reynaga DD. Nicotinic receptors in addiction pathways. Mol Pharmacol 2013;83:753-8
   PubMed Web of Science ®Google Scholar
• Tobacco Use and Dependence Guideline Panel. Treating Tobacco Use and Dependence: 2008 Update. 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK63952/ [Last Accessed 22 November 2013]
   Google Scholar
• Hughes JR. Motivating and helping smokers to stop smoking. J Gen Intern Med 2003;18:1053-7
   PubMed Web of Science ®Google Scholar
• Cohen S, Lichtenstein E, Prochaska JO, et al. Debunking myths about self-quitting. Evidence from 10 prospective studies of persons who attempt to quit smoking by themselves. Am Psychol 1989;44:1355-65
   PubMed Web of Science ®Google Scholar
• Agaku IT, King BA, Dube SR. Current cigarette smoking among adults - united states, 2005-2012. MMWR Morb Mortal Wkly Rep 2014;63:29-34
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services. Preventing tobacco use among youth and young adults: a report of the surgeon general. Department of health and human services, centers for disease control and prevention, national center for chronic disease prevention and health promotion, office on smoking and health, Atlanta GA, US; 2012
   Google Scholar
• Kendler KS, Myers J, Damaj MI, Chen X. Early smoking onset and risk for subsequent nicotine dependence: a monozygotic co-twin control study. Am J Psychiatry 2013;170:408-13
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Guide to quitting smoking. 2013. Available from: http://www.cancer.org/healthy/stayawayfromtobacco/guidetoquittingsmoking/guide-to-quitting-smoking-benefits [Last Accessed 16 February 2014]
   Google Scholar
• Centers for Disease Control and Prevention. Quitting smoking among adults--united states, 2001-2010. MMWR Morb Mortal Wkly Rep 2011;60:1513-19
   PubMedGoogle Scholar
• Lerman C, LeSage MG, Perkins KA, et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007;6:746-62
   PubMed Web of Science ®Google Scholar
• Conklin CA, Perkins KA, Sheidow AJ, et al. The return to smoking: 1-year relapse trajectories among female smokers. Nicotine Tob Res 2005;7:533-40
   PubMed Web of Science ®Google Scholar
• Fu SS, Partin MR, Snyder A, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care 2006;12:235-43
   PubMed Web of Science ®Google Scholar
• Sims TH, Fiore MC. Pharmacotherapy for treating tobacco dependence: what is the ideal duration of therapy? CNS Drugs 2002;16:653-62
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs 2010;70:2357-72
   PubMed Web of Science ®Google Scholar
• Sabaté E, editor. Adherence to long-term therapies: evidence for action Chapter XIV. World Health Organization; Geneva, Switzerland; 2003
   Google Scholar
• Hays JT, Leischow SJ, Lawrence D, Lee TC. Adherence to treatment for tobacco dependence: association with smoking abstinence and predictors of adherence. Nicotine Tob Res 2010;12:574-81
   PubMed Web of Science ®Google Scholar
• Zeng F, Chen CI, Mastey V, et al. Effects of copayment on initiation of smoking cessation pharmacotherapy: an analysis of varenicline reversed claims. Clin Ther 2011;33:225-34
   PubMed Web of Science ®Google Scholar
• Liberman JN, Lichtenfeld MJ, Galaznik A, et al. Adherence to varenicline and associated smoking cessation in a community-based patient setting. J Manag Care Pharm 2013;19:125-31
   PubMed Web of Science ®Google Scholar
• Rigotti NA. Treatment of tobacco use and dependence. N Engl J Med 2002;346:506-12
   PubMed Web of Science ®Google Scholar
• Abrams DB, Graham AL, Levy DT, et al. Boosting population quits through evidence-based cessation treatment and policy. Am J Prev Med 2010;38:S351-S63
   PubMed Web of Science ®Google Scholar
• Gollust SE, Schroeder SA, Warner KE. Helping smokers quit: understanding the barriers to utilization of smoking cessation services. Milbank Q 2008;86:601-27
   PubMed Web of Science ®Google Scholar
• Reda AA, Kaper J, Fikrelter H, et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2009(2):CD004305
   Google Scholar
• Wray JM, Gass JC, Tiffany ST. A systematic review of the relationships between craving and smoking cessation. Nicotine Tob Res 2013;15:1167-82
   PubMed Web of Science ®Google Scholar
• Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2012(11):CD000146
   Google Scholar
• West R, Hajek P, Nilsson F, et al. Individual differences in preferences for and responses to four nicotine replacement products. Psychopharmacology (Berl) 2001;153:225-30
   PubMed Web of Science ®Google Scholar
• Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet 2001;40:661-84
   PubMed Web of Science ®Google Scholar
• Hughes JR, Goldstein MG, Hurt RD, Shiffman S. Recent advances in the pharmacotherapy of smoking. JAMA 1999;281:72-6
   PubMed Web of Science ®Google Scholar
• Tonnesen P, Lauri H, Perfekt R, et al. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. Eur Respir J 2012;40:548-54
   PubMed Web of Science ®Google Scholar
• Shiffman S, Dresler CM, Rohay JM. Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy. Addiction 2004;99:83-92
   PubMed Web of Science ®Google Scholar
• Choi JH, Dresler CM, Norton MR, Strahs KR. Pharmacokinetics of a nicotine polacrilex lozenge. Nicotine Tob Res 2003;5:635-44
   PubMed Web of Science ®Google Scholar
• Ebbert JO. Varenicline and combination nicotine replacement therapy are the most effective pharmacotherapies for treating tobacco use. Evid Based Med 2013;18:212-13
   PubMedGoogle Scholar
• Carpenter MJ, Jardin BF, Burris JL, et al. Clinical strategies to enhance the efficacy of nicotine replacement therapy for smoking cessation: a review of the literature. Drugs 2013;73:407-26
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. US food and drug administration. Nicotine replacement therapy labels may change. FDA Consumer Health Information. 2013. Available from: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm345087.htm [Last Accessed 18 February 2014]
   Google Scholar
• Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009;11:234-9
   PubMed Web of Science ®Google Scholar
• Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997;337:1195-202
   PubMed Web of Science ®Google Scholar
• McCarthy DE, Piasecki TM, Lawrence DL, et al. Psychological mediators of bupropion sustained-release treatment for smoking cessation. Addiction 2008;103:1521-33
   PubMed Web of Science ®Google Scholar
• Kotlyar M, Drone D, Thuras P, et al. Effect of stress and bupropion on craving, withdrawal symptoms, and mood in smokers. Nicotine Tob Res 2011;13:492-7
   PubMed Web of Science ®Google Scholar
• Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013(5):CD009329
   Google Scholar
• Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007(1):CD000031
   PubMed Web of Science ®Google Scholar
• Farley AC, Hajek P, Lycett D, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev 2012(1):CD006219
   Google Scholar
• Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013(2):CD007253
   PubMed Web of Science ®Google Scholar
• Burke MV, Ebbert JO, Hays JT. Treatment of tobacco dependence. Mayo Clin Proc 2008;83:479-83; quiz 83-4
   PubMed Web of Science ®Google Scholar
• Mills EJ, Thorlund K, Eapen S, et al. Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation 2014;129:28-41
   PubMed Web of Science ®Google Scholar
• The FDA approves new drug for smoking cessation. FDA Consum 2006;40:29
   PubMedGoogle Scholar
• Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem 2005;48:3474-7
   PubMed Web of Science ®Google Scholar
• Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359:2018-24
   PubMed Web of Science ®Google Scholar
• Ebbert JO. Emerging drugs for the treatment of tobacco dependence. Expert Opin Emerg Drugs 2009;14:23-32
   PubMed Web of Science ®Google Scholar
• Ebbert JO, Burke MV, Hays JT, Hurt RD. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009;11:572-6
   PubMed Web of Science ®Google Scholar
• Hajek P, Smith KM, Dhanji AR, McRobbie H. Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med 2013;11:140
   PubMedGoogle Scholar
• Ebbert JO, Hatsukami DK, Croghan IT, et al. Combination varenicline and bupropion sr for tobacco-dependence treatment in cigarette smokers: a randomized trial. JAMA 2014;311:155-63
   PubMed Web of Science ®Google Scholar
• Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 2006;296:64-71
   PubMed Web of Science ®Google Scholar
• Jimenez-Ruiz CA, Barrios M, Pena S, et al. Increasing the dose of varenicline in patients who do not respond to the standard dose. Mayo Clin Proc 2013;88:1443-5
   PubMed Web of Science ®Google Scholar
• Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012(4):CD006103
   Google Scholar
• Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006;296:56-63
   PubMed Web of Science ®Google Scholar
• Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55
   PubMed Web of Science ®Google Scholar
• Kuehn BM. FDA warns of adverse events linked to smoking cessation drug and antiepileptics. JAMA 2008;299:1121-2
   PubMed Web of Science ®Google Scholar
• Page ME. The promises and pitfalls of reboxetine. CNS Drug Rev 2003;9:327-42
   PubMedGoogle Scholar
• Glassman AH, Helzer JE, Covey LS, et al. Smoking, smoking cessation, and major depression. JAMA 1990;264:1546-9
   PubMed Web of Science ®Google Scholar
• Breslau N, Peterson EL, Schultz LR, et al. Major depression and stages of smoking: a longitudinal investigation. Arch Gen Psychiatry 1998;55:161-6
   PubMed Web of Science ®Google Scholar
• Weinberger AH, Mazure CM, Morlett A, McKee SA. Two decades of smoking cessation treatment research on smokers with depression: 1990–2010. Nicotine Tob Res 2013;15:1014-31
   PubMed Web of Science ®Google Scholar
• Hughes JR, Stead LF, Lancaster T. Nortriptyline for smoking cessation: a review. Nicotine Tob Res 2005;7:491-9
   PubMed Web of Science ®Google Scholar
• Quaak M, van Schayck CP, Postma DS, et al. Genetic variants in the serotonin transporter influence the efficacy of bupropion and nortriptyline in smoking cessation. Addiction 2012;107:178-87
   PubMed Web of Science ®Google Scholar
• Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database Syst Rev 2004(3):CD000058
   PubMedGoogle Scholar
• Gehricke JG, Hong N, Wigal TL, et al. ADHD medication reduces cotinine levels and withdrawal in smokers with ADHD. Pharmacol Biochem Behav 2011;98:485-91
   PubMed Web of Science ®Google Scholar
• Silverstone PH, Dadashova R. Atomoxetine treatment for nicotine withdrawal: a pilot double-blind, placebo-controlled, fixed-dose study in adult smokers. Ann Gen Psychiatry 2012;11:6
   PubMedGoogle Scholar
• Sacco KA, Creeden C, Reutenauer EL, et al. Effects of atomoxetine on cognitive function and cigarette smoking in schizophrenia. Schizophr Res 2009;107:332-3
   PubMed Web of Science ®Google Scholar
• Dadashova R, Silverstone P. Off-label use of atomoxetine in adults: is it safe? Mental Illness 2012;4:e19
   Google Scholar
• Cousins MS, Stamat HM, de Wit H. Effects of a single dose of baclofen on self-reported subjective effects and tobacco smoking. Nicotine Tob Res 2001;3:123-9
   PubMedGoogle Scholar
• Franklin TR, Harper D, Kampman K, et al. The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study. Drug Alcohol Depend 2009;103:30-6
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Babb D, Hatsukami DK. Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers. Nicotine Tob Res 2003;5:947-53
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Mouratidis M, Yoo S, Kosten T. Adrenergic blocker carvedilol attenuates the cardiovascular and aversive effects of nicotine in abstinent smokers. Behav Pharmacol 2006;17:731-5
   PubMed Web of Science ®Google Scholar
• Stead LF, Hughes JR. Lobeline for smoking cessation. Cochrane Database Syst Rev 2012(2):CD000124
   Google Scholar
• Glover ED, Rath JM, Sharma E, et al. A multicenter phase 3 trial of lobeline sulfate for smoking cessation. Am J Health Behav 2010;34:101-9
   PubMed Web of Science ®Google Scholar
• McKee SA, Weinberger AH, Harrison EL, et al. Effects of the nicotinic receptor antagonist mecamylamine on ad-lib smoking behavior, topography, and nicotine levels in smokers with and without schizophrenia: a preliminary study. Schizophr Res 2009;115:317-24
   PubMed Web of Science ®Google Scholar
• Glover ED, Laflin MT, Schuh KJ, et al. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction 2007;102:795-802
   PubMed Web of Science ®Google Scholar
• Lancaster T, Stead LF. Mecamylamine (a nicotine antagonist) for smoking cessation. Cochrane Database Syst Rev 2000(2):CD001009
   Google Scholar
• Wong GY, Wolter TD, Croghan GA, et al. A randomized trial of naltrexone for smoking cessation. Addiction 1999;94:1227-37
   PubMed Web of Science ®Google Scholar
• Hadjiconstantinou M, Neff NH. Nicotine and endogenous opioids: neurochemical and pharmacological evidence. Neuropharmacology 2011;60:1209-20
   PubMed Web of Science ®Google Scholar
• Berrendero F, Robledo P, Trigo JM, et al. Neurobiological mechanisms involved in nicotine dependence and reward: participation of the endogenous opioid system. Neurosci Biobehav Rev 2010;35:220-31
   PubMed Web of Science ®Google Scholar
• David SP, Lancaster T, Stead LF, et al. Opioid antagonists for smoking cessation. Cochrane Database Syst Rev 2013(6):CD003086
   Google Scholar
• King A, de Wit H, Riley RC, et al. Efficacy of naltrexone in smoking cessation: a preliminary study and an examination of sex differences. Nicotine Tob Res 2006;8:671-82
   PubMed Web of Science ®Google Scholar
• Walsh Z, Epstein A, Munisamy G, King A. The impact of depressive symptoms on the efficacy of naltrexone in smoking cessation. J Addict Dis 2008;27:65-72
   PubMed Web of Science ®Google Scholar
• Foulds J, Steinberg MB, Williams JM, Ziedonis DM. Developments in pharmacotherapy for tobacco dependence: past, present and future. Drug Alcohol Rev 2006;25:59-71
   PubMed Web of Science ®Google Scholar
• Eyding D, Lelgemann M, Grouven U, et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ 2010;341:c4737
   PubMed Web of Science ®Google Scholar
• Szalavitz M. How a study of a failed antidepressant shows that antidepressants really work. Time October 18, 2010
   Google Scholar
• Cahill K, Ussher MH. Cannabinoid type 1 receptor antagonists for smoking cessation. Cochrane Database Syst Rev 2011(3):CD005353
   Google Scholar
• Merritt LL, Martin BR, Walters C, et al. The endogenous cannabinoid system modulates nicotine reward and dependence. J Pharmacol Exp Ther 2008;326:483-92
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Noble EP, Oskooilar N. ANKK1/DRD2 locus variants are associated with rimonabant efficacy in aiding smoking cessation: pilot data. J Investig Med 2011;59:1280-3
   PubMed Web of Science ®Google Scholar
• Tonstad S, Aubin HJ. Efficacy of a dose range of surinabant, a cannabinoid receptor blocker, for smoking cessation: a randomized controlled clinical trial. J Psychopharmacol 2012;26:1003-9
   PubMed Web of Science ®Google Scholar
• Killen JD, Fortmann SP, Murphy GM Jr, et al. Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy. Addiction 2010;105:1660-8
   PubMed Web of Science ®Google Scholar
• Houtsmuller EJ, Thornton JA, Stitzer ML. Effects of selegiline (L-deprenyl) during smoking and short-term abstinence. Psychopharmacology (Berl) 2002;163:213-20
   PubMed Web of Science ®Google Scholar
• George TP, Vessicchio JC, Termine A, et al. A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation. Biol Psychiatry 2003;53:136-43
   PubMed Web of Science ®Google Scholar
• Biberman R, Neumann R, Katzir I, Gerber Y. A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation. Addiction 2003;98:1403-7
   PubMed Web of Science ®Google Scholar
• Kahn R, Gorgon L, Jones K, et al. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine Tob Res 2012;14:377-82
   PubMed Web of Science ®Google Scholar
• Weinberger AH, Reutenauer EL, Jatlow PI, et al. A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers. Drug Alcohol Depend 2010;107:188-95
   PubMed Web of Science ®Google Scholar
• Syed BA, Chaudhari K. Smoking cessation drugs market. Nat Rev Drug Discov 2013;12:97-8
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Mouratidis M, Yoo S, et al. Effects of tiagabine in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2005;181:504-10
   PubMed Web of Science ®Google Scholar
• Shinn AK, Greenfield SF. Topiramate in the treatment of substance-related disorders: a critical review of the literature. J Clin Psychiatry 2010;71:634-48
   PubMed Web of Science ®Google Scholar
• Olive MF, Cleva RM, Kalivas PW, Malcolm RJ. Glutamatergic medications for the treatment of drug and behavioral addictions. Pharmacol Biochem Behav 2012;100:801-10
   PubMed Web of Science ®Google Scholar
• Khazaal Y, Cornuz J, Bilancioni R, Zullino DF. Topiramate for smoking cessation. Psychiatry Clin Neurosci 2006;60:384-8
   PubMed Web of Science ®Google Scholar
• Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med 2005;165:1600-5
   PubMed Web of Science ®Google Scholar
• Reid MS, Palamar J, Raghavan S, Flammino F. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology (Berl) 2007;192:147-58
   PubMed Web of Science ®Google Scholar
• Sofuoglu M, Poling J, Mouratidis M, Kosten T. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl) 2006;184:645-51
   PubMed Web of Science ®Google Scholar
• Anthenelli RM, Blom TJ, McElroy SL, Keck PE Jr. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction 2008;103:687-94
   PubMed Web of Science ®Google Scholar
• Baltieri DA, Daro FR, Ribeiro PL, Andrade AG. Effects of topiramate or naltrexone on tobacco use among male alcohol-dependent outpatients. Drug Alcohol Depend 2009;105:33-41
   PubMed Web of Science ®Google Scholar
• Weinberger AH, George TP, Perkins KA, Chengappa KN. Effects of topiramate on smoking in patients with schizoaffective disorder, bipolar type. J Clin Psychopharmacol 2008;28:247-8
   PubMed Web of Science ®Google Scholar
• Khazaal Y, Zullino DF. Topiramate for smoking cessation and the importance to distinguish withdrawal-motivated consumption and cue-triggered automatisms. J Clin Psychopharmacol 2009;29:192-3; author reply 3-4
   PubMed Web of Science ®Google Scholar
• Markou A, Paterson NE, Semenova S. Role of gamma-aminobutyric acid (GABA) and metabotropic glutamate receptors in nicotine reinforcement: potential pharmacotherapies for smoking cessation. Ann NY Acad Sci 2004;1025:491-503
   PubMed Web of Science ®Google Scholar
• Wickelgren I. Drug may suppress the craving for nicotine. Science 1998;282:1797-9
   PubMed Web of Science ®Google Scholar
• Etter JF. Cytisine for smoking cessation: a literature review and a meta-analysis. Arch Intern Med 2006;166:1553-9
   PubMed Web of Science ®Google Scholar
• Hajek P, McRobbie H, Myers K. Efficacy of cytisine in helping smokers quit: systematic review and meta-analysis. Thorax 2013;68:1037-42
   PubMed Web of Science ®Google Scholar
• Prochaska JJ, Das S, Benowitz NL. Cytisine, the world's oldest smoking cessation aid. BMJ 2013;347:f5198
   PubMed Web of Science ®Google Scholar
• Aveyard P, West R. Cytisine and the failure to market and regulate for human health. Thorax 2013;68:989
   PubMed Web of Science ®Google Scholar
• Vinnikov D, Brimkulov N, Burjubaeva A. A double-blind, randomised, placebo-controlled trial of cytisine for smoking cessation in medium-dependent workers. J Smok Cessat 2008;3:57-62
   Google Scholar
• West R, Zatonski W, Cedzynska M, et al. Placebo-controlled trial of cytisine for smoking cessation. N Engl J Med 2011;365:1193-200
   PubMed Web of Science ®Google Scholar
• Stapleton JA. The case for licensing cytosine now for smoking cessation is overwhelming. BMJ 2013;347:f5736
   PubMedGoogle Scholar
• Lancaster T, Stead LF. Silver acetate for smoking cessation. Cochrane Database Syst Rev 2012(9):CD000191
   Google Scholar
• Rose JE, Behm FM, Murugesan T, McClernon FJ. Silver acetate interactions with nicotine and non-nicotine smoke components. Exp Clin Psychopharmacol 2010;18:462-9
   PubMed Web of Science ®Google Scholar
• Stead LF, Lancaster T. Nicobrevin for smoking cessation. Cochrane Database Syst Rev 2006(2):CD005990
   Google Scholar
• Medicines and Healthcare Products Regulatory Agency. Drug Safety Update. Nicobrevin antismoking preparation: withdrawn from the market. 2011. Available from: http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON117324 [Last Accessed 18 February 2014]
   Google Scholar
• Hughes JR, Stead LF, Lancaster T. Anxiolytics and antidepressants for smoking cessation. Cochrane Database Syst Rev 2000(2):CD000031
   Google Scholar
• Cinciripini PM, Lapitsky L, Seay S, et al. A placebo-controlled evaluation of the effects of buspirone on smoking cessation: differences between high- and low-anxiety smokers. J Clin Psychopharmacol 1995;15:182-91
   PubMed Web of Science ®Google Scholar
• Schneider NG, Olmstead RE, Steinberg C, et al. Efficacy of buspirone in smoking cessation: a placebo-controlled trial. Clin Pharmacol Ther 1996;60:568-75
   PubMed Web of Science ®Google Scholar
• Santa Ana EJ, Rounsaville BJ, Frankforter TL, et al. D-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: a pilot investigation. Drug Alcohol Depend 2009;104:220-7
   PubMed Web of Science ®Google Scholar
• Yoon JH, Newton TF, Haile CN, et al. Effects of D-cycloserine on cue-induced craving and cigarette smoking among concurrent cocaine- and nicotine-dependent volunteers. Addict Behav 2013;38:1518-26
   PubMed Web of Science ®Google Scholar
• Mugnaini M, Iavarone L, Cavallini P, et al. Occupancy of brain dopamine d3 receptors and drug craving: a translational approach. Neuropsychopharmacology 2013;38:302-12
   PubMed Web of Science ®Google Scholar
• European College of Neuropsychopharmacology. ECNP Medicines Chest - List of Drugs. 2013. Available from: http://www.ecnp.eu/projects-initiatives/ECNP-medicines-chest/List_of_drugs.aspx [Last Accessed 20 December 2013]
   Google Scholar
• Schmaal L, Berk L, Hulstijn KP, et al. Efficacy of N-acetylcysteine in the treatment of nicotine dependence: a double-blind placebo-controlled pilot study. Eur Addict Res 2011;17:211-16
   PubMed Web of Science ®Google Scholar
• Knackstedt LA, LaRowe S, Mardikian P, et al. The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry 2009;65:841-5
   PubMed Web of Science ®Google Scholar
• Orleans CT. Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains--in our lifetime. Am J Prev Med 2007;33:S340-8
   PubMed Web of Science ®Google Scholar
• Euromonitor International. NRT Smoking Cessation Aids in the US: executive Summary. 2013. Available from: http://www.euromonitor.com/nrt-smoking-cessation-aids-in-the-us/report [Last Accessed 22 November 2013]
   Google Scholar
• Hubbard R, Lewis S, West J, et al. Bupropion and the risk of sudden death: a self-controlled case-series analysis using the health improvement network. Thorax 2005;60:848-50
   PubMed Web of Science ®Google Scholar
• Ferry LH. The power of the press in smokers' attempts to quit. BMJ 2002;324:1346-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. State medicaid coverage for tobacco-dependence treatments – United States, 2009. MMWR Morb Mortal Wkly Rep 2010;59:1340-3
   PubMedGoogle Scholar
• Turner JR, Gold A, Schnoll R, Blendy JA. Translational research in nicotine dependence. Cold Spring Harb Perspect Med 2013;3:a012153
   PubMed Web of Science ®Google Scholar
• Mackey C. Nicotine dependence treatment, DMKC0075633. Datamonitor Healthcare. Datamonitor America, New York; 2012
   Google Scholar
• D'Souza MS, Markou A. Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract 2011;6:4-16
   PubMedGoogle Scholar
• Hartmann-Boyce J, Cahill K, Hatsukami D, Cornuz J. Nicotine vaccines for smoking cessation. Cochrane Database Syst Rev 2012(8):CD007072
   Google Scholar
• Benowitz NL, Goniewicz ML. The regulatory challenge of electronic cigarettes. JAMA 2013;310:685-6
   PubMed Web of Science ®Google Scholar
• Elliott V. Despite ACA mandate, tobacco cessation not always covered. American Medical News. 2012. Available from: http://www.amednews.com/article/20121217/business/121219969/4/ [Last Accessed 4 January 2014]
   Google Scholar
• Ponder P, Jefferson A-M, Backinger C, Grana R. Tobacco-related research funding at the National Cancer Institute: portfolio analysis, fiscal year 2003. Nicotine Tob Res 2007;9:1053-7
   PubMed Web of Science ®Google Scholar
• Klee EW, Ebbert JO, Schneider H, et al. Zebrafish for the study of the biological effects of nicotine. Nicotine Tob Res 2011;13:301-12
   PubMed Web of Science ®Google Scholar
• Beronio K, Po R, Glied S; ASPE ISSUE BRIEF. Affordable Care Act Expands Mental Health and Substance Use Disorder Benefits and Federal Parity Protections for 62 Million Americans. US Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. 2013. Available from: http://aspe.hhs.gov/health/reports/2013/mental/rb_mental.cfm [Last Accessed 4 January 2014]
   Google Scholar